Russia's COVID-19 Vaccine Considered Safe in Early Human Trial: Lancet

Russian COVID-19 vaccine Sputnik V has elicited an immune response in early human trials with no adverse side effects, reports a new study.

Sputnik V, the COVID-19 vaccine, approved by Russia last month, has been shown to elicit an immune response with no serious side effects in small human trials, reports a new study. The findings of the study are published in the journal The Lancet.

Sputnik V was registered by Russia last month, becoming the first country to approve a COVID-19 vaccine. However, the country encountered criticism for approving a vaccine before the completion of Phase-3 trials.

Coronavirus
Coronaviruses infect animals, humans, and birds. Human coronaviruses, such as SARS, MERS, and 2019-nCoV cause respiratory distress and even death. The S protein is the infectious agent of the virus.

‘Russia's potential COVID-19 vaccine, Sputnik V, shows no serious adverse effects and creates an antibody response. ’

In the Lancet study, researchers reported on two small trials, each involving 38 healthy adults (aged 18-60 years), who were given a two-part immunization.

Each participant of the study was given the first part of the vaccine dose, followed by a booster. They monitored the participants over 42 days, and all developed antibodies within the first three weeks.

The vaccine was found to be safe, well tolerated, and does not cause serious unfavorable events in participants.

Safe and Efficient SARS-coronavirus Vaccine Created
Scientists show how to modify an effective live attenuated severe acute respiratory syndrome (SARS) vaccine to make it genetically stable.

Phase-3 trial of the vaccine is being planned by Russia, involving 40,000 people.

Source-Medindia

Coronavirus Vaccine Appears Safe in the First Human Trial: The Lancet
First coronavirus vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to create an immune response against SARS-CoV-2 in humans, reports a new study.

US Very Close to Testing Coronavirus Vaccine, Says Trump
US President Donald Trump while addressing the daily White House coronavirus briefing said we are very close to a vaccine , after noting vaccine trials taking place in the US, Germany.